Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

CONCLUSIONS: In summary, galunisertib treatment has an acceptable safety profile and was associated with hematologic improvements in lower- and intermediate-risk MDS, with responses in heavily transfusion-dependent patients and in those with signs of an early stem cell differentiation block. ClinicalTrials.gov, number NCT02008318. PMID: 31481511 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31481511?dopt=Abstract

Source: Clin Med Res - September 2, 2019 Category: Research Authors: Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly A, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Sridharan A, Gueorguieva I, Girvan A, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Will B, Verma A Tags: Clin Cancer Res Source Type: research